It ultimately homed in on 500 to 600 hematologists and geneticists worldwide.

FORBES: Magazine Article

Over time, it hopes to convince hematologists to use Tasigna first.

FORBES: Pipelines

At a big meeting of hematologists today, Novartis unveiled data from an 846-patient trial showing that Tasigna was more effective than Gleevec in early-stage leukemia patients.

FORBES: Pipelines

"There is reason to wonder how the use of an obscure recombinant coagulation factor marketed exclusively to hematologists came to be used so widely by cardiac surgeons, neurologists and trauma specialists, " they said.

WSJ: Hemophilia Drug's Off-Label Use Is Faulted